The KLK14 response to DHT and enzalutamide likely proposes a functional component as to the resistance mechanisms of AR inhibitors; additional assays also show that active KLK14 is secreted from both osteoblasts and PCa cells to promote tumor cell migration. The gene discussed is KLK14; the disease is posterior cortical atrophy.